MeiraGTx (MGTX) said Wednesday that the US Food and Drug Administration has granted its AAV8-RK-RetGC program rare pediatric disease designation for treating Leber congenital amaurosis caused by GUCY2D mutations (LCA1).
The company said it has received this fourth rare pediatric disease designation in the past three months, following similar designations for treatments targeting LCA4 retinal dystrophy, Bardet-Biedl syndrome, and RDH12-associated retinal dystrophy.
The designation is given to drugs for rare diseases affecting fewer than 200,000 patients, primarily those under 18. If a company gains approval for a treatment for a rare pediatric disease, it may receive a voucher for priority review of a future application, the company added.
Price: 6.13, Change: -0.28, Percent Change: -4.37
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。